Cargando…
Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies
Kidney toxicity accounts for a significant percentage of morbidity and drug candidate failure. Serum creatinine (SCr) and blood urea nitrogen (BUN) have been used to monitor kidney dysfunction for over a century but these markers are insensitive and non-specific. In multi-site preclinical rat toxico...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885849/ https://www.ncbi.nlm.nih.gov/pubmed/20458318 http://dx.doi.org/10.1038/nbt.1623 |
_version_ | 1782182416142565376 |
---|---|
author | Vaidya, Vishal S. Ozer, Josef S. Frank, Dieterle Collings, Fitz B. Ramirez, Victoria Troth, Sean Muniappa, Nagaraja Thudium, Douglas Gerhold, David Holder, Daniel J. Bobadilla, Norma A. Marrer, Estelle Perentes, Elias Cordier, André Vonderscher, Jacky Maurer, Gérard Goering, Peter L. Sistare, Frank D. Bonventre, Joseph V. |
author_facet | Vaidya, Vishal S. Ozer, Josef S. Frank, Dieterle Collings, Fitz B. Ramirez, Victoria Troth, Sean Muniappa, Nagaraja Thudium, Douglas Gerhold, David Holder, Daniel J. Bobadilla, Norma A. Marrer, Estelle Perentes, Elias Cordier, André Vonderscher, Jacky Maurer, Gérard Goering, Peter L. Sistare, Frank D. Bonventre, Joseph V. |
author_sort | Vaidya, Vishal S. |
collection | PubMed |
description | Kidney toxicity accounts for a significant percentage of morbidity and drug candidate failure. Serum creatinine (SCr) and blood urea nitrogen (BUN) have been used to monitor kidney dysfunction for over a century but these markers are insensitive and non-specific. In multi-site preclinical rat toxicology studies the diagnostic performance of urinary kidney injury molecule-1 (Kim-1) was compared to traditional biomarkers as predictors of kidney tubular histopathologic changes, currently considered the “gold standard” of nephrotoxicity. In multiple models of kidney injury, urinary Kim-1 significantly outperformed SCr and BUN. The area under the receiver operating characteristic curve for Kim-1 was between 0.91 and 0.99 as compared to 0.79 to 0.9 for BUN and 0.73 to 0.85 for SCr. Thus urinary Kim-1 is the first injury biomarker of kidney toxicity qualified by the FDA and EMEA and is expected to significantly improve kidney safety monitoring. |
format | Text |
id | pubmed-2885849 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
record_format | MEDLINE/PubMed |
spelling | pubmed-28858492010-11-01 Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies Vaidya, Vishal S. Ozer, Josef S. Frank, Dieterle Collings, Fitz B. Ramirez, Victoria Troth, Sean Muniappa, Nagaraja Thudium, Douglas Gerhold, David Holder, Daniel J. Bobadilla, Norma A. Marrer, Estelle Perentes, Elias Cordier, André Vonderscher, Jacky Maurer, Gérard Goering, Peter L. Sistare, Frank D. Bonventre, Joseph V. Nat Biotechnol Article Kidney toxicity accounts for a significant percentage of morbidity and drug candidate failure. Serum creatinine (SCr) and blood urea nitrogen (BUN) have been used to monitor kidney dysfunction for over a century but these markers are insensitive and non-specific. In multi-site preclinical rat toxicology studies the diagnostic performance of urinary kidney injury molecule-1 (Kim-1) was compared to traditional biomarkers as predictors of kidney tubular histopathologic changes, currently considered the “gold standard” of nephrotoxicity. In multiple models of kidney injury, urinary Kim-1 significantly outperformed SCr and BUN. The area under the receiver operating characteristic curve for Kim-1 was between 0.91 and 0.99 as compared to 0.79 to 0.9 for BUN and 0.73 to 0.85 for SCr. Thus urinary Kim-1 is the first injury biomarker of kidney toxicity qualified by the FDA and EMEA and is expected to significantly improve kidney safety monitoring. 2010-05 /pmc/articles/PMC2885849/ /pubmed/20458318 http://dx.doi.org/10.1038/nbt.1623 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Vaidya, Vishal S. Ozer, Josef S. Frank, Dieterle Collings, Fitz B. Ramirez, Victoria Troth, Sean Muniappa, Nagaraja Thudium, Douglas Gerhold, David Holder, Daniel J. Bobadilla, Norma A. Marrer, Estelle Perentes, Elias Cordier, André Vonderscher, Jacky Maurer, Gérard Goering, Peter L. Sistare, Frank D. Bonventre, Joseph V. Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies |
title | Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies |
title_full | Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies |
title_fullStr | Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies |
title_full_unstemmed | Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies |
title_short | Kidney Injury Molecule-1 Outperforms Traditional Biomarkers of Kidney Injury in Multi-site Preclinical Biomarker Qualification Studies |
title_sort | kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in multi-site preclinical biomarker qualification studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2885849/ https://www.ncbi.nlm.nih.gov/pubmed/20458318 http://dx.doi.org/10.1038/nbt.1623 |
work_keys_str_mv | AT vaidyavishals kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT ozerjosefs kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT frankdieterle kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT collingsfitzb kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT ramirezvictoria kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT trothsean kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT muniappanagaraja kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT thudiumdouglas kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT gerholddavid kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT holderdanielj kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT bobadillanormaa kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT marrerestelle kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT perenteselias kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT cordierandre kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT vonderscherjacky kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT maurergerard kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT goeringpeterl kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT sistarefrankd kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies AT bonventrejosephv kidneyinjurymolecule1outperformstraditionalbiomarkersofkidneyinjuryinmultisitepreclinicalbiomarkerqualificationstudies |